Platelet microparticles and soluble P selectin in peripheral artery disease: Relationship to extent of disease and platelet activation markers

2005 ◽  
Vol 37 (1) ◽  
pp. 61-66 ◽  
Author(s):  
Kiat T. Tan ◽  
Muzahir H. Tayebjee ◽  
Cheryl Lynd ◽  
Andrew D. Blann ◽  
Gregory Y. H. Lip
Keyword(s):  
Peripheral Artery Disease ◽  
Platelet Activation ◽  
Peripheral Artery ◽  
Activation Markers ◽  
Soluble P ◽  
Artery Disease ◽  
Extent Of Disease ◽  
Platelet Microparticles

Soluble CD40L in peripheral artery disease

2005 ◽  
Vol 93 (03) ◽  
pp. 578-583 ◽  
Author(s):  
Kiat Tan ◽  
Muzahir Tayebjee ◽  
Indran Davagnanam ◽  
Mark Moss ◽  
Gregory Lip ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Sole Source ◽  
Clinical Severity ◽  
Healthy Controls ◽  
Peripheral Artery ◽  
Platelet Surface ◽  
Soluble Cd40l ◽  
Soluble P ◽  
Artery Disease

SummaryAlthough soluble CD40L (sCD40L, possibly derived from platelets and pro-inflammatory in vitro) may be implicated in thrombosis and haemostasis, there are little data in peripheral artery disease (PAD). We hypothesised the following: (a) that sCD40L relates to the clinical severity of PAD; and (b) that peripheral artery angioplasty acutely raises sCD40L levels. sCD40L was compared to established platelet markers soluble P selectin, platelet microparticles and platelet surface expression of CD62 and CD63. We recruited 36 healthy controls, 33 patients with intermittent claudication (IC), and 33 with symptomatically more severe critical limb is chaemia (CLI), measuring plasma markers by ELISA and membrane markers by flow cytometry. Eleven patients with CLI subsequently underwent peripheral artery angioplasty: blood was taken before and 10 minutes after the intervention. Results show that sCD40L was raised in IC at median 68 (IQR 28–333) pg/ml and in CLI at 64 (34–282) pg/mL compared to 35 (IQR 28–55) pg/ml in the healthy controls (p=0.009). Levels were no different between IC and CLI. The same distribution pattern was present for soluble P selectin, %platelets CD62+ve and CD63+ve. sCD40L failed to correlate significantly with ABPI (p=0.264), unlike %platelets CD62+ve (p=0.0032) and CD63+ve (p=0.009). Pre-angioplasty sCD40L level of 72 (35–610) ng/ml rose to 100 ng/ml (IQR=60–237)(p=0.018) post–angioplasty. Plasma sCD40L, in addition to other platelet indices, is raised in peripheral atherosclerosis and is increased by peripheral artery angioplasty, although levels seem unrelated to clinical severity. Failure to correlate with other markers suggest the platelet may not be the sole source of sCD40L, and that other cells may contribute to plasma levels.

scholarly journals Differential platelet oxidation-inflammatory phenotype in coronary artery disease versus peripheral artery disease supports diverse pathophysiological processes

2020 ◽  
Author(s):  
Kanika Jain ◽  
Tarun Tyagi ◽  
John Hwa ◽  
Costin Ionescu
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Peripheral Artery Disease ◽  
Platelet Activation ◽  
Peripheral Artery ◽  
P2y12 Inhibitors ◽  
Inflammatory Parameters ◽  
Inflammatory Status ◽  
Inflammatory Phenotype ◽  
Artery Disease

Abstract Platelets are major contributors to atherothrombosis. There is emerging evidence that atherothrombosis pathogenesis may be different between vascular beds. In a prospective case-control study, we compared platelet oxidation-inflammatory status from patients with coronary artery disease CAD, peripheral artery disease (PAD) and a young healthy cohort. All patients had stable disease with no recent acute CAD or PAD events. Assessment of 75 eligible patients revealed a typical outpatient cardiology cohort. A significant increase in platelet activation (soluble P-selectin and CD40L) was seen in CAD. Consistent with this platelet activation, the CAD group had the highest levels of oxidants (reactive oxygen species, lipid peroxidation and protein carbonylation) and the lowest levels of antioxidants (catalase and superoxide dismutase enzyme activity). IL1bwas significantly increased in the PAD group. The significant differences in the oxidation-inflammatory parameters, between patients with CAD versus PAD, may explain different atherothrombosis pathology, as well differential response to therapies, such as aspirin and P2Y12 inhibitors. Whether these are the cause or consequence of disease or both, requires further extensive exploration. Such mechanistic understanding is important in developing disease targeted therapies.

scholarly journals Epicatechin and Catechin Modulate Endothelial Activation Induced by Platelets of Patients with Peripheral Artery Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
R. Carnevale ◽  
L. Loffredo ◽  
C. Nocella ◽  
S. Bartimoccia ◽  
T. Bucci ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Platelet Activation ◽  
Initial Step ◽  
Endothelial Activation ◽  
Peripheral Artery ◽  
Soluble Cell ◽  
Activated Platelets ◽  
Enos Phosphorylation ◽  
No Bioavailability ◽  
Artery Disease

Platelet activation contributes to the alteration of endothelial function, a critical initial step in atherogenesis through the production and release of prooxidant mediators. There is uncertainty about the precise role of polyphenols in interaction between platelets and endothelial cells (ECs). We aimed to investigate whether polyphenols are able to reduce endothelial activation induced by activated platelets. First, we compared platelet activation and flow-mediated dilation (FMD) in 10 healthy subjects (HS) and 10 patients with peripheral artery disease (PAD). Then, we evaluated the effect of epicatechin plus catechin on platelet-HUVEC interaction by measuring soluble cell adhesion molecules (CAMs), NOx production, and eNOS phosphorylation (p-eNOS) in HUVEC. Compared to HS, PAD patients had enhanced platelet activation. Conversely, PAD patients had lower FMD than HS. Supernatant of activated platelets from PAD patients induced an increase of sCAMs release and a decrease of p-eNOS and nitric oxide (NO) bioavailability compared to unstimulated HUVEC. Coincubation of HUVEC, with supernatant of PAD platelets patients, pretreated with a scalar dose of the polyphenols, resulted in a decrease of sCAMs release and in an increase of p-eNOS and NO bioavailability. This study demonstrates that epicatechin plus catechin reduces endothelial activation induced by activated platelets.

scholarly journals Plasma Levels of snoRNAs are Associated with Platelet Activation in Patients with Peripheral Artery Disease

2019 ◽  
Vol 20 (23) ◽  
pp. 5975
Author(s):  
Anne Yaël Nossent ◽  
Neda Ektefaie ◽  
Johann Wojta ◽  
Beate Eichelberger ◽  
Christoph Kopp ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Peripheral Artery Disease ◽  
Platelet Activation ◽  
Stent Implantation ◽  
Plasma Levels ◽  
Peripheral Artery ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Surgical Interventions ◽  
Artery Disease

In addition to supervised walking therapy, antithrombotic therapy and the management of risk factors, the treatment of peripheral artery disease (PAD) is limited to endovascular and surgical interventions, i.e., angioplasty with stent implantation and bypass surgery, respectively. Both are associated with a high restenosis rate. Furthermore, patients with PAD often suffer atherothrombotic events like myocardial infarction, transient ischemic attacks or stroke. Small ribonucleic acids (RNAs) have proven reliable biomarkers because of their remarkable stability. Small nucleolar RNAs (snoRNAs) guide modifications to small nuclear RNAs and ribosomal RNAs, enabling protein synthesis. In the current study, we measured four snoRNAs in 104 consecutive PAD patients who underwent elective infrainguinal angioplasty with stent implantation. We selected snoRNAs that showed significant overexpression in the plasma of end-stage PAD patients in a previous study. All four snoRNAs are transcribed from the 14q32 locus, which is strongly linked to human cardiovascular disease, including PAD and restenosis. We showed that the four selected 14q32 snoRNAs were abundantly expressed in the plasma of PAD patients. The plasma levels of these snoRNAs were not directly associated with target vessel restenosis, however, levels of SNORD113.2 and SNORD114.1 were strongly linked to platelet activation, which is an important determinant of long-term outcome, in PAD, and in cardiovascular disease in general.

Associations of coronary and peripheral artery disease with presence, expansion, and rupture of abdominal aortic aneurysm – a grin without a cat!

VASA ◽  
2017 ◽  
Vol 46 (3) ◽  
pp. 151-158 ◽  
Author(s):  
Hisato Takagi ◽  
Takuya Umemoto
Keyword(s):  
Abdominal Aortic Aneurysm ◽  
Aortic Aneurysm ◽  
Peripheral Artery Disease ◽  
Literature Search ◽  
Systematic Literature Search ◽  
Peripheral Artery ◽  
Epidemiological Evidence ◽  
Abdominal Aortic ◽  
Artery Disease ◽  
Meta Analyses

Abstract. Both coronary and peripheral artery disease are representative atherosclerotic diseases, which are also known to be positively associated with presence of abdominal aortic aneurysm. It is still controversial, however, whether coronary and peripheral artery disease are positively associated with expansion and rupture as well as presence of abdominal aortic aneurysm. In the present article, we overviewed epidemiological evidence, i. e. meta-analyses, regarding the associations of coronary and peripheral artery disease with presence, expansion, and rupture of abdominal aortic aneurysm through a systematic literature search. Our exhaustive search identified seven meta-analyses, which suggest that both coronary and peripheral artery disease are positively associated with presence of abdominal aortic aneurysm, may be negatively associated with expansion of abdominal aortic aneurysm, and might be unassociated with rupture of abdominal aortic aneurysm.

Sign in / Sign up

Export Citation Format

Share Document